Q4 2024 Management View CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Noting that CLL and RT represented the key value drivers in his model for GLPG, Frommer argued that GLPG5101 has yet to generate clinical data against both indications where rivalry for a new CD ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

The remaining Galapagos entity will specialize in cell therapy, focusing on its lead CAR-T candidate, GLPG5101, currently being tested for relapsed or refractory non-Hodgkin lymphoma. Additionally ...

“With the FDA’s IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma ...

"With the FDA's IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma indications, there is ...